Three landmark clinical diabetes studies all concluded that maintaining mean blood glucose (MBG) levels at or about normal levels can reduce the risk for developing diabetes complications such as eye, kidney and nerve disease by as much as 72%. Maintaining "Tight Control" is important in all forms of diabetes. Reduce your risk for complications by routinely monitoring your A1c level.
The AccuBase Hemoglobin A1c Test by Diabetes Technologies (Model 881001) uses a unique and highly specialized multi-method laboratory analysis (HPLC-IE/BA) to evaluate your A1c level. The two (2) step process includes a screening step to detect hemoglobin variants and/or disturbed erythrocyte kinetics (DEK) by HPLC-Ion Exchange (IE). The second step includes the use of an interference-free procedure HPLC-Boronate Affinity (BA), that provides an A1c value free of possible interferences including chemically modified derivatives. This multi-method of the Diabetes Technologies AccuBase Hemoglobin A1c Test provides the most comprehensive evaluation of individual hematology surrounding A1c as the most recent inference of glycemic control by any laboratory or method available in the U.S.
A proper Hemoglobin A1c determination should always include the evaluation of the individuals Red Blood Cells at the time of A1c measurement. The Diabetes Technologies AccuBase multi-method analysis does this and more.
While the normal range of a non-diabetic individual is in this range, individuals with diabetes should use extreme caution when maintaining A1c levels below 5.0% as this may represent a significant opportunity for hypoglycemia (especially in individuals that present with hypoglycemia unawareness).
The DCCT and other diabetes studies have concluded that there is an direct association with the risk for the possible development of complications with increasing levels of A1c.
Any elevation in mean blood glucose concentration above 5.5 percent (108 mg/dl) should be explained by a physician. A1c level of 5.6 - 5.9 percent: The individual level of mean blood glucose has exceeded the normal upper limit of the assay range, indicating an abnormality in the expected normal human range. While this level is not recognized by the ADA as diagnostic of diabetes, the individual level does signal a level that may be indicative of impaired glucose tolerance (IGT) and/or pre-diabetes.
Anyone with an A1c in this range should seek medical attention to determine the cause of the elevation in mean blood glucose. This is an important early warning sign that could prevent an individual from becoming diabetic if caught early. Often, diet and/or exercise may reverse and/or reduce the A1c level back to within normal range.
Other important diagnostic tests, examinations and evalu ations include: an annual dilated retinal examination, microalbumin, monitoring for ketones, foot examination, thyroid evaluation, and other tests as recommended by your physician, the American Diabetes Association and/or your health care plan provider.
A1c testing should not replace or be a substitute for daily blood glucose monitoring or routine visits to the physician and/or diabetes health care team. Testing should not replace or be a substitute for daily blood glucose monitoring or routine visits to the physician and/or diabetes health care team. The AccuBase A1c Test Kit is designed to provide the physician and patient with an accurate and convenient method for the assessment of the average glucose concentration (mean blood glucose) in the body during the past 90 days.
| Hemoglobin A1c Home Blood Mail In Test | |
|---|---|
30 day stability of sample after collection |
Allows remote collection |
Above normal levels |
Greater than 5.6 % mg/dl (greater than 109 mg/dl) |
An A1c Level of 6.0% (126 mg/dl) or greater |
An A1c level of 6.0% or greater represents a high risk for diabetes mellitus. It is recommended that the individual seek immediate medial attention to discuss the cause of the elevated glucose level. There are confounding factors that can cause elevation |
Detects sample degradation |
Displaying abnormal or displaced peaks |
Highly precise measurement |
(< 2% CVs) 1.68 at 6.1 % and .68 at 9.5% |
Identifies out of range samples |
< 3M or > 5M RBCs |
Interference free method |
No Refrigeration of test kits required |
Interpretation of A1c levels when screening mean blood glucose (MBG) |
An important assumption of any monitoring of A1c should include the recognition that the analytical method and testing laboratory should be certified by the National Glycohemoglobin Standardization Program (NGSP), certifying that their CV's are no greater |
Meets diabetes screening sensitivity requirement |
< 2.0% CVs |
Narrow non-diabetic range |
(4.2% - 6.0%) 70 = 108 mg/dl |
NGSP certified (method and testing laboratory) |
NGSP Level I certification |
No drying time required |
Reduces technical errors |
Normal HPLC-BA non-diabetic range |
4.3 - 5.5 % (70 - 108 mg/dl) |
Normal human glucose levels |
4.3 - 5.5 % (70 - 108 mg/dl) |
Patient chromatogram print out |
Allows visualization of total area peaks |
Recommended ordering frequency of Hemoglobin A1c |
According to the American Diabetes Association and the American Association of Clinical Endocrinologists, A1c should be routinely monitored in individuals with diabetes mellitus at least every 90 days. Ordering frequency of A1c may depend on the type of d |
Results Interpretation |
Interpretation of Individual test results and setting of individual A1c goals should be jointly discussed between the physician and patient at routine office visits. The presence of hypoglycemia unawareness should be a serious consideration when setting i |
Risk levels for developing possible diabetes complications associated with A1c levels |
Below normal levels: levels <4.3 % (70 mg/dl) indicate an serious risk for acute hypoglycemia (low blood sugar levels). High risk level for acute hypoglycemia. |
Shelf Life |
2 years, highly precise |
This item does not come with a warranty.
This item is non returnable if opened, used or expired.
If item is found defective by the manufacturer, an exchange or refund will be offered.
81035 Loss of Protective Sensation Test for the Foot
|






|
|
|
|
|
|
||
Registered with Washington Department of Veteran Affairs: www.dva.wa.gov |
|||||||